Restatement

9 Months Ended

Dec. 31, 2024

Accounting Changes and Error Corrections [Abstract]

Restatement

Note 3 – Restatement

As of December 31, 2023, the Company’s subsidiary RXCompound carried a goodwill in the amount of $138,312, and it was included in intangible assets, and amortized, such amortization is being reversed, and the below set forth tables reflect the effect in the Company’s Consolidated Balance Sheet, Consolidated Statement of Stockholders’ Equity, and Consolidated Statement of Operations.

Adjustments to Consolidated Balance Sheet as of December 31, 2023

Consolidated Balance Sheet

	As of December 31, 2023
	December 31, 2023, before restatement		Restatement		December 31, 2023, after restatement
Total Assets	$	3,245,655	$	38,269	$	3,283,924
Total stockholders’ Equity		2,159,383		38,269		2,197,652

Adjustments to Consolidated Statement of Stockholders’ Equity for the six months ended December 31, 2023

Consolidated Statement of Stockholders’ Equity

	For the nine months ended December 31, 2023
	December 31, 2023, before restatement			Restatement		December 31, 2023, after restatement
Accumulated deficit	$	(29,922,668	)	$	38,269	$	(29,884,399	)
Stockholders’ Equity		2,159,383			38,269		2,197,652

Adjustments to Consolidated Statement of Operations for the nine months ended December 31, 2023

Consolidated Statement of Operations

	For the nine months ended December 31, 2023
	December 31, 2023, before restatement		Restatement		December 31, 2023, after restatement
Net Income	$	580,315	$	2,500	$	582,815